导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.51% | 2342/4773 |
| 近一周 | -2.30% | 1720/5462 |
| 近一月 | -4.75% | 2702/5421 |
| 近一季 | 12.39% | 114/5209 |
| 近半年 | -0.45% | 1305/4920 |
| 近一年 | -14.12% | 3635/4366 |
| 近两年 | 23.91% | 2543/2954 |
| 近三年 | -16.46% | 2100/2253 |
| 成立以来 | -50.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.74% 2887/4961 |
-6.47% 3702/5312 |
- - |
- - |
| 2025 | 4.18% 3065/4813 |
3.09% 1200/3635 |
-1.41% 3153/4076 |
17.47% 2494/4524 |
-12.75% 4274/4813 |
| 2024 | -15.51% 2480/3463 |
-13.83% 2501/2808 |
-10.49% 2451/3014 |
21.41% 587/3129 |
-9.77% 2950/3463 |
| 2023 | -22.80% 1940/2656 |
-2.28% 1951/2280 |
-14.38% 2237/2385 |
-1.55% 544/2515 |
-6.28% 1700/2655 |
| 2022 | -23.67% 1158/2207 |
-16.45% 1130/1919 |
3.24% 1186/2016 |
-17.96% 1665/2113 |
7.86% 286/2208 |
| 2021 | -11.65% 1114/1822 |
-2.25% 607/1255 |
22.98% 121/1330 |
-16.79% 1404/1466 |
-11.68% 1613/1822 |
| 2020 | - - |
- - |
- - |
- - |
11.44% 541/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证医疗ETF联接C VS. 长安沪深300非周期A(740101) |